USANA Health Sciences Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Jim Brown

Algemeen directeur

US$2.5m

Totale compensatie

Percentage CEO-salaris	28.7%
Dienstverband CEO	8yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	7.8yrs
Gemiddelde ambtstermijn bestuur	6.7yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Jim Brown's beloning veranderd ten opzichte van USANA Health Sciences's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 28 2024	n/a	n/a	US$54m
Jun 29 2024	n/a	n/a	US$55m
Mar 30 2024	n/a	n/a	US$62m
Dec 30 2023	US$2m	US$710k	US$64m
Sep 30 2023	n/a	n/a	US$60m
Jul 01 2023	n/a	n/a	US$63m
Apr 01 2023	n/a	n/a	US$65m
Dec 31 2022	US$2m	US$624k	US$69m
Oct 01 2022	n/a	n/a	US$77m
Jul 02 2022	n/a	n/a	US$89m
Apr 02 2022	n/a	n/a	US$108m
Jan 01 2022	US$2m	US$600k	US$117m
Oct 02 2021	n/a	n/a	US$136m
Jul 03 2021	n/a	n/a	US$139m
Apr 03 2021	n/a	n/a	US$129m
Jan 02 2021	US$2m	US$599k	US$125m
Sep 26 2020	n/a	n/a	US$116m
Jun 27 2020	n/a	n/a	US$110m
Mar 28 2020	n/a	n/a	US$103m
Dec 28 2019	US$2m	US$559k	US$101m
Sep 28 2019	n/a	n/a	US$102m
Jun 29 2019	n/a	n/a	US$109m
Mar 30 2019	n/a	n/a	US$121m
Dec 29 2018	US$2m	US$534k	US$126m
Sep 29 2018	n/a	n/a	US$88m
Jun 30 2018	n/a	n/a	US$81m
Mar 31 2018	n/a	n/a	US$70m
Dec 30 2017	US$1m	US$523k	US$63m

Compensatie versus markt: De totale vergoeding ($USD 2.47M ) Jim } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 1.44M ).

Compensatie versus inkomsten: De beloning van Jim is het afgelopen jaar met meer dan 20% gestegen, terwijl de winst van het bedrijf met meer dan 20% is gedaald.

CEO

Jim Brown (55 yo)

8yrs

Tenure

US$2,472,017

Compensatie

Mr. Jim Brown has been the President of USANA Health Sciences Inc. since November 2016 and served as its Chief Operating Officer since November 2013 until October 2019. He serves as Chief Executive Officer...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Kevin Guest	Executive Chairman	7.5yrs	US$3.91m	0.064% € 462.9k
Jim Brown	CEO & President	8yrs	US$2.47m	geen gegevens
G. Hekking	Chief Financial Officer	7.5yrs	US$1.47m	geen gegevens
Walter Noot	Chief Operating Officer	5.1yrs	US$1.42m	geen gegevens
P. Foukas	Chief Legal Officer	6.3yrs	US$1.29m	geen gegevens
Daniel Macuga	Chief Communications & Marketing Officer	12.9yrs	US$1.15m	geen gegevens
Myron Wentz	Founder & Chairman Emeritus	32.8yrs	geen gegevens	40.62% € 294.3m
John Cuomo	Executive Director of Product Development & Technology	11.9yrs	geen gegevens	geen gegevens
Robert Sinnott	Chief Scientific Officer	8.3yrs	geen gegevens	geen gegevens
Peter Benedict	Chief Information Officer	no data	geen gegevens	geen gegevens
Patrique Richards	Executive Director of Investor Relations & Business Development	no data	geen gegevens	geen gegevens
Paul Jones	Chief People Officer	3.8yrs	US$637.78k	0% € 0

7.8yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van USJ is doorgewinterd en ervaren (gemiddelde ambtstermijn van 7.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Kevin Guest	Executive Chairman	7.5yrs	US$3.91m	0.064% € 462.9k
Myron Wentz	Founder & Chairman Emeritus	4.5yrs	geen gegevens	40.62% € 294.3m
Gilbert Fuller	Lead Independent Director	16.2yrs	US$251.60k	geen gegevens
Peggie Pelosi	Independent Director	5.9yrs	US$231.40k	0.021% € 149.1k
Timothy Wood	Independent Director	5.1yrs	US$218.40k	0.034% € 244.5k
Christine Wood	Member of Scientific Advisory Council	no data	geen gegevens	geen gegevens
Monica Lewis	Member of Scientific Advisory Council	no data	geen gegevens	geen gegevens
Peter Rugg	Chairperson of Scientific Advisory Council	20.8yrs	geen gegevens	geen gegevens
Bart Moore	Member of Scientific Advisory Council	no data	geen gegevens	geen gegevens
Heather Tick	Member of Scientific Advisory Council	no data	geen gegevens	geen gegevens
Frederic Winssinger	Independent Director	8.5yrs	US$233.60k	0.024% € 171.9k
J. Nixon	Independent Director	2.3yrs	US$218.40k	0.022% € 161.0k

6.7yrs

Gemiddelde duur

68yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van USJ wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.7 jaar).

USANA Health Sciences Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Chief People Officer recently sold €220k worth of stock

Founder & Chairman Emeritus recently sold €166k worth of stock

Chief People Officer recently sold €122k worth of stock

Chief Financial Officer recently sold €216k worth of stock

Insider recently sold €167k worth of stock

USANA Health Sciences, Inc., Annual General Meeting, May 06, 2024

Recent updates

Third quarter 2024 earnings released: EPS: US$0.56 (vs US$0.59 in 3Q 2023)

USANA Health Sciences, Inc. Updates Consolidated Earnings Guidance for the Fiscal Year 2024

USANA Health Sciences, Inc. to Report Q3, 2024 Results on Oct 22, 2024

USANA Health Sciences, Inc. Launches New, Innovative Skincare and Protein Products Resurfacing Serum and Whey Protein Isolate Up the Game for USANA

Chief People Officer recently sold €220k worth of stock

New major risk - Revenue and earnings growth

Now 22% undervalued

Second quarter 2024 earnings released: EPS: US$0.55 (vs US$0.90 in 2Q 2023)

USANA Health Sciences, Inc. to Report Q2, 2024 Results on Jul 23, 2024

Founder & Chairman Emeritus recently sold €166k worth of stock

Chief People Officer recently sold €122k worth of stock

Chief Financial Officer recently sold €216k worth of stock

Insider recently sold €167k worth of stock

First quarter 2024 earnings released: EPS: US$0.86 (vs US$0.95 in 1Q 2023)

USANA Health Sciences, Inc. to Report Q1, 2024 Results on Apr 30, 2024

USANA Health Sciences, Inc., Annual General Meeting, May 06, 2024

Chief Legal Officer recently sold €215k worth of stock

Full year 2023 earnings released: EPS: US$3.31 (vs US$3.60 in FY 2022)

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Full year 2023 earnings released: EPS: US$3.30 (vs US$3.60 in FY 2022)

USANA Health Sciences, Inc. Provides Earnings Guidance for the Fiscal Year 2024

USANA Health Sciences, Inc. to Report Q4, 2023 Results on Feb 06, 2024

Investor sentiment deteriorates as stock falls 17%

USANA Health Sciences, Inc. Revises Earnings Guidance for the Year 2023

Third quarter 2023 earnings released: EPS: US$0.59 (vs US$0.78 in 3Q 2022)

USANA Health Sciences, Inc. to Report Q3, 2023 Results on Oct 24, 2023

Now 20% undervalued after recent price drop

Now 21% undervalued after recent price drop

Chief People Officer recently sold €217k worth of stock

USANA Health Sciences, Inc. Updates Earnings Guidance for the Year 2023

Second quarter 2023 earnings released: EPS: US$0.89 (vs US$1.00 in 2Q 2022)

USANA Health Sciences, Inc. to Report Q2, 2023 Results on Jul 25, 2023

USANA Health Sciences, Inc. to Report Q2, 2023 Results on Jul 25, 2023

Insufficient new directors

Insider recently sold €736k worth of stock

Independent Director recently sold €149k worth of stock

First quarter 2023 earnings released: EPS: US$0.95 (vs US$1.16 in 1Q 2022)

Chairman of the Board & CEO recently sold €301k worth of stock

Kevin Guest to Transit to the Role of Executive Chairman of USANA Health Sciences, Inc., Effective July 1, 2023

Insider recently sold €108k worth of stock

Full year 2022 earnings released: EPS: US$3.59 (vs US$5.78 in FY 2021)

Usana Health Sciences, Inc. Reiterates Consolidated Earnings Guidance for the Fiscal Year 2023

USANA Health Sciences, Inc. to Report Q4, 2022 Results on Feb 07, 2023

Insider recently sold €76k worth of stock

USANA Health Sciences, Inc. (NYSE:USNA) acquired Rise Bar and Oola Global, LLC.

Third quarter 2022 earnings released: EPS: US$0.78 (vs US$1.37 in 3Q 2021)

USANA Health Sciences, Inc. Revises Consolidated Earnings Guidance for the Year 2022

USANA Health Sciences, Inc. to Report Q3, 2022 Results on Oct 25, 2022

Chief People Officer recently sold €346k worth of stock

Chief Financial Officer recently sold €75k worth of stock

USANA Health Sciences, Inc. Announces Rejoining of J. Scott Nixon to Board of Directors

USANA Health Sciences, Inc. Reiterates Earnings Guidance for the Fiscal Year 2022

Second quarter 2022 earnings released: EPS: US$1.00 (vs US$1.89 in 2Q 2021)

USANA Health Sciences, Inc. to Report Q2, 2022 Results on Jul 26, 2022

Insider recently sold €95k worth of stock

First quarter 2022 earnings released: EPS: US$1.15 (vs US$1.47 in 1Q 2021)

USANA Health Sciences, Inc. Revises Earnings Guidance for Fiscal Year 2022

USANA Health Sciences, Inc. to Report Q1, 2022 Results on Apr 26, 2022

USANA Health Sciences, Inc., Annual General Meeting, May 09, 2022

Chief Legal Officer recently sold €268k worth of stock

Chief Operating Officer recently sold €214k worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

USANA Health Sciences, Inc. Provides Consolidated Earnings Guidance for the Fiscal Year 2022

Chief Sales Officer recently sold €79k worth of stock

Chief Sales Officer recently sold €110k worth of stock

Third quarter 2021 earnings released: EPS US$1.36 (vs US$1.45 in 3Q 2020)

USANA Health Sciences, Inc. Provides Earnings Guidance for the Third Quarter of 2021

Independent Director recently sold €51k worth of stock